Trial Domains

Comparisons

Highlighted claims

• The vanguard phase included five active domains with open-label 1:1 randomisation. — Assessing the feasibility of a platform trial for Gram negative bloodstream infections: results from the vanguard phase of BALANCE+
• The de-escalation domain compared continued empiric Gram negative antibiotic treatment with switching to narrower-spectrum therapy after susceptibility results. — Assessing the feasibility of a platform trial for Gram negative bloodstream infections: results from the vanguard phase of BALANCE+
• The oral transition domain compared oral beta-lactams with non-beta-lactam agents. — Assessing the feasibility of a platform trial for Gram negative bloodstream infections: results from the vanguard phase of BALANCE+
• The follow-up blood culture domain compared routine blood culture at 4 ± 1 days with cultures only when clinically indicated. — Assessing the feasibility of a platform trial for Gram negative bloodstream infections: results from the vanguard phase of BALANCE+
• The catheter domain compared central venous catheter replacement within 72 hours of susceptibility results with retention until no longer clinically needed. — Assessing the feasibility of a platform trial for Gram negative bloodstream infections: results from the vanguard phase of BALANCE+
• The low-risk AmpC domain compared ceftriaxone with carbapenems for Serratia, Morganella, and Providencia bloodstream infections. — Assessing the feasibility of a platform trial for Gram negative bloodstream infections: results from the vanguard phase of BALANCE+